Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
FDA’s list of off-patent drugs suggests higher approvals of first generics in 2022
We usher in 2023 with the key highlights of the US Food and Drug Administration’s December 202
Chinese industrial activity revival at 98.6 percent, officials assure of API supplies
While the world feels the heat of the Covid-19 pandemic with the global pharmaceutical supply chain
Pharma Deals, Investments and M&As in January 2018
As we come to an end of the shortest month of the year, we are
back this week with another edition o
FDA proposes delayed track and trace rollout; GSK forays into artificial intelligence-aided drug research
This week, Phispers brings you news on an apex court ruling in Canada that overhauls its patent law
Teva CEO steps down; FDA Warning Letters to firms in Japan, India & China
This week, Phispers highlights more bad news for Israeli drugmaker Teva, along with news on the &lsq
Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?
Over
700 commonly used generic medicines were
recommended for suspension by the European Medic
